Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 621 to 630 of 2260 total matches.

Correction: Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016  (Issue 1488)
In Table 1 of our February 1, 2016 article Drugs for Acne (Med Lett Drugs Ther 2016; 58:13 ...
In Table 1 of our February 1, 2016 article Drugs for Acne (Med Lett Drugs Ther 2016; 58:13), the formulations for Differin, topical adapalene, should have been listed as 0.1% gel, cream, lotion; 0.3% gel (not 3% gel).
Med Lett Drugs Ther. 2016 Feb 15;58(1488):24 | Show Introduction Hide Introduction

Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
The FDA has approved rolapitant (Varubi – Tesaro), an oral substance P/neurokinin 1 (NK1) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):17-8 | Show Introduction Hide Introduction

Drugs for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
This common, chronic inflammatory facial eruption of unknown cause is more prevalent in women than in men. Rosacea is characterized by erythema and telangiectasia, and sometimes by recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. Some patients develop granulomas and tissue hypertrophy, which may lead to rhinophyma (a bulbous nose), particularly in men. Blepharitis and conjunctivitis are common. Keratitis and corneal scarring occur rarely.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):16-7 | Show Introduction Hide Introduction

Addendum: Timing of Levothyroxine

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
In our October 26, 2015 article on drugs for hypothyroidism (Med Lett Drugs Ther 2015; 57:147), we said that levothyroxine should be taken on an empty stomach with a full glass of water 30-60 minutes (60 is preferable) before breakfast. We should have added that taking the drug consistently at bedtime, at least 3 hours after the last meal, is an alternative that some patients may find more convenient.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):18 | Show Introduction Hide Introduction

Elvitegravir (Vitekta) for HIV

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
inhibitor (PI) plus ritonavir and other antiretroviral drugs for treatment of HIV-1 infection in treatment ...
The FDA has approved elvitegravir (Vitekta – Gilead), an integrase strand transfer inhibitor (INSTI), for use with a protease inhibitor (PI) plus ritonavir and other antiretroviral drugs for treatment of HIV-1 infection in treatment-experienced adults. Elvitegravir is also available in a fixed-dose combination (Stribild) with the pharmacokinetic enhancer cobicistat and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate (DF). A similar combination (Genvoya) that includes tenofovir alafenamide instead of tenofovir...
Med Lett Drugs Ther. 2016 Jan 18;58(1486):10-1 | Show Introduction Hide Introduction

Mepolizumab (Nucala) for Severe Eosinophilic Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
have severe disease with high eosinophil levels in blood and sputum despite treatment with a glucocorticoid.1 ...
The FDA has approved mepolizumab (Nucala - GSK), a subcutaneously injected humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for maintenance treatment of severe asthma in patients ≥12 years old who have an eosinophilic phenotype.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):11-2 | Show Introduction Hide Introduction

Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
makes them good targets for intralesional viral immunotherapy.1,2 Talimogene laherparepvec (T-VEC ...
The FDA has approved talimogene laherparepvec (Imlygic – Amgen), a genetically modified herpes simplex virus, for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that has recurred following surgery. It is the first oncolytic virotherapy to become available in the US.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):8-9 | Show Introduction Hide Introduction

Durlaza - A 24-Hour Extended-Release Aspirin

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
at the end of the 24-hour dosing interval.1 An ER formulation that releases acetylsalicylic acid (ASA) over ...
The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):7 | Show Introduction Hide Introduction

Fluad - An Adjuvanted Seasonal Influenza Vaccine for Older Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
adults; Fluzone High-Dose was the first.1 Fluad has been available in other countries for many years ...
The FDA has approved Fluad (Seqirus), an adjuvanted trivalent seasonal influenza vaccine, for immunization of adults ≥65 years old. It will become available later this year for use during the 2016-2017 influenza season. Fluad is the second influenza vaccine to be approved in the US specifically for older adults; Fluzone High-Dose was the first. Fluad has been available in other countries for many years.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):8 | Show Introduction Hide Introduction

Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
to conventional therapy, but its use has been limited by serious GI adverse effects such as ischemic colitis.1 ...
The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5 | Show Introduction Hide Introduction